Moxifloxacin: Clinical efficacy and safety

Electrocardiographic Method for Identifying Drug-induced Repolarization Abnormalities Associated with a Reduction of the Rapidly Activating Delayed Rectifier Potassium Current

“…This safety assessment is based on a clinical trial specifically designed for identifying druginduced QT prolongation: such studies are called "thorough QT studies" (tQTS). Because there is no standard for the technique used in measuring the QT interval from the surface ECG [2], the Agency requires that the QTmeasurement technique be validated on a positive control group consisting of groups of healthy individuals on an antibiotic drug called moxifloxacin that is known to prolong Manuscript the QT interval of 5-10 msec [3].…”

Efficacy and Safety of Adjunctive Local Moxifloxacin Delivery in the Treatment of Periodontitis

“…It exerts a bactericidal effect by specifically inhibiting adenosine triphosphate–dependent topoisomerase IV and topoisomerase II (DNA gyrase) 3 . Moxifloxacin is used in the treatment of respiratory infections, including community‐acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, 4 and acute sinusitis, particularly in areas where drug‐resistant Streptococcus pneumonia or Haemophilus influenza are common 5 . It also has been shown to be effective in the treatment of odontogenic abscesses, 6 multidrug‐resistant viridians groups Streptococcus osteomyelitis of the mandible, 7 and complicated intra‐abdominal infections 8 .…”

Principles of Safety Pharmacology

“…In an overwhelming majority of TQT studies, moxifloxacin, a fluoroquinolone antibiotic with a mild QT-prolonging effect (Culley et al 2001), has been used. In an overwhelming majority of TQT studies, moxifloxacin, a fluoroquinolone antibiotic with a mild QT-prolonging effect (Culley et al 2001), has been used.…”